Lexicon Pharmaceuticals, Inc. — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012; balance-sheet comparisons are to December 31, 2011. Lexicon is a biopharmaceutical company with five drug programs in clinical development. The interim financial statements are unaudited.
Financial performance
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Revenue | $0.300 million | $0.596 million |
| Research and development expense | $23.037 million | $23.921 million |
| Increase in fair value of Symphony Icon liability | $2.081 million | $1.058 million |
| General and administrative expense | $4.565 million | $4.753 million |
| Operating loss | $29.383 million | $29.136 million |
| Net loss | $29.868 million | $29.629 million |
| Net loss per share | $0.06 | $0.09 |
| Net cash used in operating activities | $27.002 million | $21.540 million |
Revenue fell 50%, mainly as collaborative research revenue declined; subscription and license fees increased, primarily due to technology license fees. R&D expense decreased 4%: higher external development costs were offset by lower personnel and facilities costs. Net loss increased slightly, while loss per share narrowed because the weighted-average share count rose to 480.3 million from 337.5 million. The filing does not report a gross margin; given the small revenue base and substantial operating expenses, conventional margin comparisons are not meaningful.
Financial position and liquidity
- Cash and cash equivalents were $29.010 million and short-term investments were $224.646 million at March 31, totaling $253.656 million, versus $281.692 million at year-end. Cash and equivalents declined sharply as funds shifted into investments; total cash and investments declined by $28.036 million.
- Total assets were $402.792 million; total liabilities were $133.821 million; stockholders’ equity was $268.971 million. Accumulated deficit was $819.489 million.
- Operating activities used $27.002 million. Investing activities used $129.575 million, including $129.341 million of net investment purchases. Financing activities used $0.722 million. Cash and cash equivalents decreased $157.299 million, largely reflecting investment purchases rather than operating outflow.
- Mortgage principal outstanding was $24.5 million, at a fixed 8.23% rate. Balance-sheet current and long-term debt totaled $24.541 million. Current assets of $258.985 million substantially exceeded current liabilities of $20.933 million.
Outlook, risks, and notable items
- Management said current unrestricted cash and investments, together with expected collaboration, license, and other receipts, should fund operations for at least 12 months. Future capital needs remain substantial; if operating cash is inadequate, Lexicon may need additional equity, debt, or credit financing, which may be unavailable or dilutive.
- The company expects continued significant R&D spending and losses and says profitability will require substantially higher revenue. Revenue depends on collaborations, licenses, milestones, royalties, and partners’ development and commercialization success; results may fluctuate materially.
- The $2.081 million increase in the Symphony Icon purchase consideration liability was a non-cash fair-value charge based on Level 3 inputs. Under the purchase-option agreement, additional base and contingent payments may be due; base payments are payable at Lexicon’s discretion before July 30, 2013, and payment amounts depend partly on program expenses and licensing or regulatory outcomes.
- Other disclosed risks include clinical and regulatory uncertainty, reliance on collaborators and third parties, intellectual-property and product-commercialization risks, potential need for additional financing, and Invus’s controlling ownership and influence. Management reported no legal proceedings expected to have a material adverse effect.
- Management stated disclosure controls were effective and reported no significant changes in internal controls. The filing gives no specific financial guidance beyond the liquidity outlook.
Key facts for investors to verify
- Whether cash burn and the $253.7 million cash-and-investment balance remain consistent with the stated minimum 12-month funding outlook.
- Progress and spending for the five clinical programs, and the timing and likelihood of collaboration, licensing, milestone, or royalty receipts.
- The amount, timing, and potential share dilution or cash impact of Symphony Icon payments and changes in their fair-value estimate.
- Drivers of the year-over-year increase in operating cash use and whether expense reductions can offset rising external development costs.
- Mortgage repayment obligations, financing alternatives, and the effects of continuing losses and potential future share issuance.